Nature sub-magazine review sourd depth! Advances in preclinical research on genome-oriented cancer therapies!

, June 29, 2020/PR
Newswire/ -- In a recent review published in the international journal nature cancer,, scientists from the Wellcome Sanger Institute discussed preclinical research on genome-oriented cancer therapyProgress; Since qurtilla mitrematolym was approved forbreast cancertreatment more than 20 years ago, researchers have developed a variety of clinically effective targeted anticancer therapies, reviewing progress in genome-oriented drug development and proposing the concept of cancer gene addiction, which considers non-cancergene addictionAnd how synthetic lethalization models expand the scope of new treatments, especially cancers that are currently not treated with drugs, the paper also discusses how CRISPR-basedgeneticscreening enhances their ability to identify new targets, and finally how to expand the search and use of precision cancer drugsPhoto Credit: Francies, H.E, et alNat Cancerdoi:10.1038/s43018-020-0067-x
in which researchers discussed "
genomicsmake the development of anticancer drugs possible," "Classic Cancer Gene Addiction," "Non-Cancer Gene Addiction Research," and now researchers are accelerating their research into how genetic screening can be used to find therapeutic targets for disease, and it's not clear how many synthetic lethal interactions exist in cancer cellsBased on the researchers' study of model organisms such asyeast, taking into account the genetic, tissue, and histological heterogeneous nature of human cancer, as well as the number of geneticinteractionsadvanced stages, it seems that the scale and in many cases specific of synthetic lethal interactions appears to be large and in many cases specific, so it may be important to map the susceptibility of cancer cells, such as cancer dependence, to understand the synthetic lethality of multiple cancer cells, and thus guide the development of more precise therapiesStudies have now identified hundreds of background-specific adaptive genes in cancer cells, some of which are shared between cancer cell lines and some private, and researchers now know little about the basis of most of the different dependent moleculesIn addition, researchers conducting pairs of genetic interference studies, such as simultaneously knocking out or silencing two genes, can shed light on their relationships and help explain the synthetic lethal effects observed in heterogeneous cell lines, and thus identify more combinations of candidate targets, and so far many studies have only suggested preliminary understandings of synthetic-lethal interactions in multiple cancersestablishing a causal and mechanism association between a jump target and disease-related phenotypes is the first step in drug discovery, and for many existing and emerging targets, researchers are not quite sure about molecular changes in cancer cells that lead to different dependencies and clinical responses, and so far most preclinical/clinical studies have been able to link single somatic cell mutations, copy number compilations, and gene expression to targets, and in the context of cell pathways, polyvarius genomicssystems biologymethods that integrate epigenome,proteomics
, and phenotype data can help researchers gain a comprehensive understanding of targeted biology and therapeutic responses, and use tools such as drug or gene knockout to illustrate the adaptive responses of cancer cells that can increasingly be articulated at single-cell resolution using techniques such as single-cell RNA sequencing, which may help researchers gain an in-depth analysis of the dynamic and heterogeneous cell processes of mediated dependence and therapeutic responsesmost existing anticancer drugs are able to target small familys of proteins, such as protein kinases, and many emerging synthetic lethal targets are considered to be difficult to target, so-called unavailable drug targets; Promising new technologies include PROTAC (protein hydrolysis targeted tint), where dual-function molecules can bind to targeted proteins and E3 ubiquitin connecting enzymes, so that they can target the action protein for protein enzyme degradation, the first to enter theclinical trialis aRV-100, which can target the action of the male hormone receptor in the metastatic anti-risk prostate cancer environment degradationStudies such as Target2035, which aims to produce chemical tools and probes for targeted protein groups, may help identify new targets by developing potential selective compounds over the past 20 years, genome-oriented therapies have made significant advances in patient care, and while later challenges, such as the heterogeneity and resistance of tumor , have been used to gain an in-depth understanding of synthetic lethal interactions through a framework of cancer and non-cancergene addiction, which may in the future help researchers develop more rational targeted anticancer therapies In addition, the development of powerful new tools such as CRISPR gene editing, as well as advances in cell culture and computer methods, researchers have begun to understand the effects of synthetic lethal interactions under multiple molecular settings, which, of course, presents some challenges to later research, but with the deepening of research and the development and use of new tools, the development of later genome-oriented therapies will accelerate (BioValleyBioon.com) References: Francies, H.E., McDermott, U and Garnett, M.J Genomics-guided pre-clinical development of cancer the
Nat Cancer 1, 482-492 (2020) doi: 10.1038/s43018-020-0067-x
.